Cargando…

Naloxone availability in independent community pharmacies in Georgia, 2019

BACKGROUND: Increasing the availability of naloxone among people who use opioids, and friends and family of past and present people who use opioids is a vitally important mission to reduce the occurrence of opioid-related overdose deaths. The purpose of this study was to determine the availability o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilbert, Lauren, Elliott, Jennifer, Beasley, Lauren, Oranu, Ekene, Roth, Kimberly, Nguyễn, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379837/
https://www.ncbi.nlm.nih.gov/pubmed/34419089
http://dx.doi.org/10.1186/s13011-021-00402-w
_version_ 1783741089510850560
author Gilbert, Lauren
Elliott, Jennifer
Beasley, Lauren
Oranu, Ekene
Roth, Kimberly
Nguyễn, Jennifer
author_facet Gilbert, Lauren
Elliott, Jennifer
Beasley, Lauren
Oranu, Ekene
Roth, Kimberly
Nguyễn, Jennifer
author_sort Gilbert, Lauren
collection PubMed
description BACKGROUND: Increasing the availability of naloxone among people who use opioids, and friends and family of past and present people who use opioids is a vitally important mission to reduce the occurrence of opioid-related overdose deaths. The purpose of this study was to determine the availability of naloxone in independent community pharmacies in Georgia. Secondary objectives include determining pharmacists’ knowledge regarding the standing order and ability to counsel regarding naloxone. METHODS: A cross-sectional study using a secret shopper approach with phone contact was conducted over a period of 10 months. The study was population based and was conducted at all independent pharmacies in the state of Georgia. All independent community pharmacies in the state of Georgia were contacted and asked the naloxone questions with a 96% response rate (n = 520). RESULTS: Five hundred fifty-eight independent community pharmacies were called, with a 96% response rate (n = 520 pharmacies). Two hundred-twenty pharmacies reported having naloxone in stock. Of the 335 pharmacists asked, 174 (51.9%) incorrectly said that a prescription was required. The mean (SD) cash price was $148.02 (27.40), with a range of $0 to $300. Of 237 pharmacists asked who had naloxone in stock or who stated they could get naloxone in stock, 212 stated that they could demonstrate how to use it, 8 stated they could not, and 17 said that they possibly could or were unsure how to use it. CONCLUSIONS: This study provided insight into the limited availability of naloxone at independent community pharmacies in Georgia after the standing order was issued. The majority of pharmacists at independent pharmacies in Georgia were not using the publicly available state naloxone standing order. Additionally, the low availability of naloxone and its high cost for uninsured individuals are significant structural barriers for reducing opioid-related mortality.
format Online
Article
Text
id pubmed-8379837
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83798372021-08-23 Naloxone availability in independent community pharmacies in Georgia, 2019 Gilbert, Lauren Elliott, Jennifer Beasley, Lauren Oranu, Ekene Roth, Kimberly Nguyễn, Jennifer Subst Abuse Treat Prev Policy Research BACKGROUND: Increasing the availability of naloxone among people who use opioids, and friends and family of past and present people who use opioids is a vitally important mission to reduce the occurrence of opioid-related overdose deaths. The purpose of this study was to determine the availability of naloxone in independent community pharmacies in Georgia. Secondary objectives include determining pharmacists’ knowledge regarding the standing order and ability to counsel regarding naloxone. METHODS: A cross-sectional study using a secret shopper approach with phone contact was conducted over a period of 10 months. The study was population based and was conducted at all independent pharmacies in the state of Georgia. All independent community pharmacies in the state of Georgia were contacted and asked the naloxone questions with a 96% response rate (n = 520). RESULTS: Five hundred fifty-eight independent community pharmacies were called, with a 96% response rate (n = 520 pharmacies). Two hundred-twenty pharmacies reported having naloxone in stock. Of the 335 pharmacists asked, 174 (51.9%) incorrectly said that a prescription was required. The mean (SD) cash price was $148.02 (27.40), with a range of $0 to $300. Of 237 pharmacists asked who had naloxone in stock or who stated they could get naloxone in stock, 212 stated that they could demonstrate how to use it, 8 stated they could not, and 17 said that they possibly could or were unsure how to use it. CONCLUSIONS: This study provided insight into the limited availability of naloxone at independent community pharmacies in Georgia after the standing order was issued. The majority of pharmacists at independent pharmacies in Georgia were not using the publicly available state naloxone standing order. Additionally, the low availability of naloxone and its high cost for uninsured individuals are significant structural barriers for reducing opioid-related mortality. BioMed Central 2021-08-21 /pmc/articles/PMC8379837/ /pubmed/34419089 http://dx.doi.org/10.1186/s13011-021-00402-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Gilbert, Lauren
Elliott, Jennifer
Beasley, Lauren
Oranu, Ekene
Roth, Kimberly
Nguyễn, Jennifer
Naloxone availability in independent community pharmacies in Georgia, 2019
title Naloxone availability in independent community pharmacies in Georgia, 2019
title_full Naloxone availability in independent community pharmacies in Georgia, 2019
title_fullStr Naloxone availability in independent community pharmacies in Georgia, 2019
title_full_unstemmed Naloxone availability in independent community pharmacies in Georgia, 2019
title_short Naloxone availability in independent community pharmacies in Georgia, 2019
title_sort naloxone availability in independent community pharmacies in georgia, 2019
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379837/
https://www.ncbi.nlm.nih.gov/pubmed/34419089
http://dx.doi.org/10.1186/s13011-021-00402-w
work_keys_str_mv AT gilbertlauren naloxoneavailabilityinindependentcommunitypharmaciesingeorgia2019
AT elliottjennifer naloxoneavailabilityinindependentcommunitypharmaciesingeorgia2019
AT beasleylauren naloxoneavailabilityinindependentcommunitypharmaciesingeorgia2019
AT oranuekene naloxoneavailabilityinindependentcommunitypharmaciesingeorgia2019
AT rothkimberly naloxoneavailabilityinindependentcommunitypharmaciesingeorgia2019
AT nguyenjennifer naloxoneavailabilityinindependentcommunitypharmaciesingeorgia2019